Cargando…

Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease

The selection of optimum statin intensity is inconclusive, and the association of plasma exposure of statins and metabolites with major adverse cardiovascular events (MACEs) is unclear. This study sought to compare the effect of low (quartile 1), intermediate (quartiles 2 and 3), and high (quartile...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xiao-hong, Cai, Li-yun, Lai, Wei-Hua, Bai, Xue, Liu, Yi-bin, Zhu, Qian, He, Guo-dong, Chen, Ji-Yan, Huang, Min, Zhou, Zhi-ling, Zhong, Shi-long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267016/ https://www.ncbi.nlm.nih.gov/pubmed/32536863 http://dx.doi.org/10.3389/fphar.2020.00675

Ejemplares similares

High Plasma Exposure of Statins Associated With Increased Risk of Contrast-Induced Acute Kidney Injury in Chinese Patients With Coronary Artery Disease
por: Cai, Liyun, et al.
Publicado: (2018)

Addition of Plasma Myeloperoxidase and Trimethylamine N-Oxide to the GRACE Score Improves Prediction of Near-Term Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction
por: Tan, Yu, et al.
Publicado: (2021)

Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents
por: Bibi, Salma, et al.
Publicado: (2022)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Effect of Statins on Major Adverse Cardiovascular Events in Patients with Coronary Artery Spasm: A Meta-Analysis of the Asia Region
por: Zhao, Tian-Jun, et al.
Publicado: (2023)

Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study
por: Højlund, Mikkel, et al.
Publicado: (2022)

Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases
por: Chen, Jianqiao, et al.
Publicado: (2022)

Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes
por: Xie, Gaoqiang, et al.
Publicado: (2017)

Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients
por: Zhu, Ling, et al.
Publicado: (2020)

Impact of statin use on major adverse cardiovascular events in patients with normal stress myocardial perfusion imaging and elevated coronary artery calcium score
por: To, Yi Hui, et al.
Publicado: (2022)

The Pharmacogenetics of Statin Therapy on Clinical Events: No Evidence that Genetic Variation Affects Statin Response on Myocardial Infarction
por: Trompet, Stella, et al.
Publicado: (2022)

Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease
por: Dregoesc, Mihaela Ioana, et al.
Publicado: (2022)

Red Yeast Rice Preparations Reduce Mortality, Major Cardiovascular Adverse Events, and Risk Factors for Metabolic Syndrome: A Systematic Review and Meta−analysis
por: Yuan, Rong, et al.
Publicado: (2022)

The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins
por: Mo, Huanbiao, et al.
Publicado: (2019)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus
por: Fu, Liyao, et al.
Publicado: (2021)

Predicting Adverse Drug Events in Chinese Pediatric Inpatients With the Associated Risk Factors: A Machine Learning Study
por: Yu, Ze, et al.
Publicado: (2021)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Genetic Polymorphisms and Adverse Events on Unbound Imatinib and Its Active Metabolite Concentration in Patients With Gastrointestinal Stromal Tumors
por: Qian, Yi, et al.
Publicado: (2019)

Patterns of statin adherence in primary cardiovascular disease prevention during the pandemic
por: Malo, Sara, et al.
Publicado: (2022)

Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention
por: Chen, Zhihao, et al.
Publicado: (2018)

Risk factors for major adverse cardiovascular events after the first acute coronary syndrome
por: Okkonen, Marjo, et al.
Publicado: (2021)

Plasma Big Endothelin-1 Level Predicted 5-Year Major Adverse Cardiovascular Events in Patients With Coronary Artery Ectasia
por: Cai, Zhongxing, et al.
Publicado: (2021)

Risk of major adverse events associated with gabapentinoid and opioid combination therapy: A systematic review and meta-analysis
por: Hahn, Jongsung, et al.
Publicado: (2022)

A prognostic nomogram for long-term major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention
por: Kong, Shuting, et al.
Publicado: (2021)

Plasma Gut Microbe-Derived Metabolites Associated with Peripheral Artery Disease and Major Adverse Cardiac Events
por: Ho, Karen J., et al.
Publicado: (2022)

Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis
por: Hong, Namki, et al.
Publicado: (2018)

Chinese Herbal Medicines and Active Metabolites: Potential Antioxidant Treatments for Atherosclerosis
por: Song, Luxia, et al.
Publicado: (2021)

Effect of the index of cardiac electrophysiological balance on major adverse cardiovascular events in patients with diabetes complicated with coronary heart disease
por: Lin, Yuan, et al.
Publicado: (2023)

Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis
por: Chaiyasothi, Thanaputt, et al.
Publicado: (2019)

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
por: Vuorio, Alpo, et al.
Publicado: (2023)

Current Progress of Studies of Coronary CT for Risk Prediction of Major Adverse Cardiovascular Event (MACE)
por: Zheng, Jianan, et al.
Publicado: (2021)

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
por: Liang, Zhe, et al.
Publicado: (2021)

Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study
por: Zhang, Lisha, et al.
Publicado: (2019)

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes
por: Regan, Jessica A., et al.
Publicado: (2023)

Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol
por: Blais, Joseph E, et al.
Publicado: (2020)

Risk factors for major adverse cardiovascular events after coronary artery bypass grafting using radial artery grafts
por: Xia, Tianyu, et al.
Publicado: (2023)

Plasma Metabolites and Gut Microbiota Are Associated With T cell Imbalance in BALB/c Model of Eosinophilic Asthma
por: Zhou, Yumei, et al.
Publicado: (2022)

Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention
por: Cai, Anping, et al.
Publicado: (2019)

Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
por: Wei, Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ufm7tgirb1gjthsep3jgj06toc